- Published on
Toxicology: Testosterone and Methyltestosterone
BASICS
DESCRIPTION
Testosterone is a naturally produced androgen responsible for the development and maintenance of male reproductive characteristics. Testosterone and synthetic anabolic-androgenic steroids may also be misused to increase muscle mass, alter appearance, or improve athletic performance.
FORMS AND USES
Anabolic-androgenic steroids may be used nonmedically by adolescents, athletes, and bodybuilders. Veterinary steroid products may also be obtained and misused.
Some users combine several steroid preparations, a practice called stacking. Others alternate periods of use with drug-free intervals, commonly referred to as cycling.
TOXIC DOSE
There is no single toxic dose applicable to all testosterone and methyltestosterone exposures. The likelihood and severity of adverse effects depend on the preparation, dose, duration of use, route of administration, and individual susceptibility.
Serious toxic effects are more often associated with repeated or prolonged misuse than with a single acute exposure.
PATHOPHYSIOLOGY
Excessive androgen exposure can influence central nervous system function and may contribute to irritability, aggression, and other behavioral disturbances.
Long-term anabolic-androgenic steroid misuse can also adversely affect cardiovascular health through changes in lipid metabolism, thrombotic risk, and processes that contribute to atherosclerotic disease.
EPIDEMIOLOGY
Nonmedical anabolic-androgenic steroid use has been reported among athletes, bodybuilders, and individuals seeking changes in physical appearance. The frequency of misuse varies among populations, and not every exposure results in clinical poisoning.
CAUSES
Most clinically important adverse effects are associated with chronic nonmedical use or the administration of high doses. Severe toxicity following an isolated acute ingestion is comparatively uncommon.
PREGNANCY AND LACTATION
Androgenic medications may cause fetal harm, including masculinization of a female fetus, and should not be used for nonmedical purposes during pregnancy.
The original reference classified these agents under the former US FDA Pregnancy Category X. This letter-based system has been replaced by narrative pregnancy and lactation risk labeling.
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
Assessment is based on the exposure history, the particular product used, and findings compatible with androgen excess. Clinicians should also consider other drugs, supplements, endocrine disorders, and causes of cardiovascular or psychiatric symptoms.
SIGNS AND SYMPTOMS
Dermatologic: Increased sebum production may lead to acne, folliculitis, and recurrent boils or furunculosis.
Cardiovascular: Thrombotic events and myocardial infarction have been reported in association with anabolic-androgenic steroid misuse.
Gastrointestinal: Nausea and vomiting may occur.
Hepatic: Cholestatic liver injury and hepatic tumors, including hepatocellular adenomas, have been reported, particularly with certain orally active anabolic steroids.
Musculoskeletal: In children and adolescents, exposure may accelerate skeletal maturation and prematurely close growth plates, limiting final adult height.
Neurologic: Cerebrovascular events, including stroke, may occur in association with vascular complications.
Genitourinary: Suppression of endogenous reproductive hormones may cause testicular dysfunction, hypogonadism, reduced sperm production, or absence of sperm in semen.
Endocrine and metabolic: Adverse lipid changes may include increased low-density lipoprotein (LDL) cholesterol and decreased high-density lipoprotein (HDL) cholesterol. External androgen administration may suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
In males, gynecomastia and impaired spermatogenesis may occur. In females, androgenic effects may include scalp hair loss, hirsutism, voice deepening, clitoral enlargement, menstrual cessation, and reduced breast size. Some virilizing changes may be irreversible.
Psychiatric: Mood elevation, irritability, aggression, manic symptoms, and, occasionally, psychotic symptoms have been described. Depressive symptoms may develop after discontinuation, particularly following prolonged high-dose use.
PROCEDURES AND LABORATORY TESTS
ESSENTIAL TESTS
Routine laboratory testing may not be necessary for an asymptomatic individual following an isolated exposure. Investigations should be tailored to the clinical presentation and any suspected coingestants.
RECOMMENDED TESTS
Liver function tests and a lipid profile may help assess complications of ongoing steroid exposure.
Hormone testing, including testosterone, LH, and FSH, may be useful when endocrine suppression is suspected. Specialized testosterone-to-epitestosterone ratios may be used in anti-doping assessment, but are not a stand-alone clinical test for toxicity.
Patients with chest pain, neurological deficits, or other signs of ischemia require prompt cardiovascular or neurological evaluation, as appropriate.
Semen analysis may be considered when impaired fertility is a concern. Specific urine testing may identify certain exogenous anabolic steroids when the result would alter management.
TESTS GENERALLY NOT RECOMMENDED
A single isolated steroid concentration often provides little useful information about clinical severity and should not replace assessment of symptoms and complications.
TREATMENT
Management is mainly supportive and directed toward the presenting clinical problem. Severe effects after a one-time ingestion are unusual, but suspected cardiovascular, hepatic, endocrine, or psychiatric complications require appropriate assessment and treatment.
DIRECTING PATIENT CARE
Poison control consultation: Seek specialist advice when symptoms are severe or persistent, when other substances may have been taken, or when drug interactions or underlying illness complicate management.
Referral to a healthcare facility: Emergency assessment is appropriate when intentional self-harm, deliberate poisoning of another person, significant symptoms, or complex coexposures are suspected.
Admission considerations: Hospital admission may be necessary for myocardial ischemia, stroke, severe psychiatric manifestations, or other significant complications. Patients with marked withdrawal-related mood symptoms may require specialist psychiatric or addiction care.
DECONTAMINATION
Outside the hospital: Do not induce vomiting. Emesis is not an appropriate response to suspected steroid ingestion.
In the hospital: The historical source discussed gastric lavage and activated charcoal after very large oral ingestions. These interventions are not routine treatment for isolated anabolic-androgenic steroid exposure; their use, if considered at all, should follow current toxicology guidance and a case-specific assessment of risks and benefits.
ANTIDOTES
There is no specific antidote for testosterone or methyltestosterone toxicity.
ADJUNCTIVE TREATMENT
Psychiatric assessment may be warranted after intentional overdose or in patients experiencing significant behavioral or mood disturbances. Counseling and treatment for problematic anabolic-androgenic steroid use may also be indicated.
FOLLOW-UP
PATIENT MONITORING
Continuous monitoring is usually unnecessary after an uncomplicated acute exposure in an asymptomatic person. Follow-up may be required when chronic misuse has caused cardiovascular, hepatic, reproductive, or psychiatric effects.
EXPECTED COURSE AND PROGNOSIS
An isolated acute ingestion generally produces limited effects and is often followed by complete recovery. Outcomes following prolonged misuse depend on the nature and severity of complications, some of which may persist after exposure stops.
DISCHARGE
CRITERIA AND INSTRUCTIONS
From the emergency department: Patients who remain well, have no concerning associated exposures, and do not require further investigation may be discharged after suitable clinical assessment. Mental health evaluation is appropriate when self-harm is suspected.
From the hospital: Discharge may be considered once acute complications have stabilized or resolved and an appropriate follow-up plan is in place.
PITFALLS AND LONG-TERM FOLLOW-UP
People who inject anabolic-androgenic steroids should be offered assessment for blood-borne infections, including HIV and viral hepatitis, when relevant to their injection practices.
Patients with nonmedical steroid use should be assessed for dependence, withdrawal symptoms, and associated psychological or physical harms. Supportive counseling and, when necessary, referral to addiction services are important aspects of longer-term care.
ICD-9-CM CLASSIFICATION
962 — Poisoning by hormones and synthetic substitutes (historical ICD-9-CM category).
Clinical note: This article paraphrases historical source material. Older diagnostic thresholds, pregnancy categories, and decontamination procedures should not be treated as current clinical guidance.